Table 1

General features of the studies included in the analysis

First author
(year)ref
CountryStudy designPatients
(n)
Age
(years)
Men (%)
(Clo/Tic)
DM (%)
(Clo/Tic)
HTN (%)
(Clo/Tic)
HLD (%)
(Clo/Tic)
Smokers (%)
(Clo/Tic)
Follow-upPatientsInterventions
Li (2015)3 ChinaRCT15762.964.6/60.3100/10040/37.535/30/6 monthsACSTicagrelor 90 mg once daily
Chen (2016)4 ChinaRCT9863.057.1/61.2100/100///6 monthsACSTicagrelor 90 mg once daily
Xu (2016)5 ChinaRCT8061.160/62.537.5/32.538.8/32.734.7/38.853.1/57.16 monthsACSTicagrelor 45 mg twice daily
Jin et al (2017)6 ChinaRCT11259.853.6/46.4////12 monthsACSTicagrelor 90 mg once daily
Hao et al (2017)7 ChinaRCT20365.568.9/70.854.4/53.1///12 monthsACSTicagrelor 90 mg once daily
Choi et al (2017)9 KoreaRCT6262.4/25/20/1860/55/415/10/1830/55/2328 daysACSTicagrelor 45 mg twice daily or ticagrelor 90 mg once daily
Park et al (2018)11 KoreaRCT43//////30 daysACSTicagrelor 60 mg twice daily
Dimitrios et al (2017)12 GreeceRCT2058.5/7090/3514 daysACSTicagrelor 60 mg twice daily
Sun (2017)19 ChinaRCT7856.466.7/64.1////30 daysACSTicagrelor 90 mg once daily
Hu (2017)20 ChinaRCT5269.6/42.3/34.6///3 monthsACSTicagrelor 45 mg twice daily
Liao (2017)21 ChinaRCT16063.955/53.8////3 monthsACSTicagrelor 90 mg once daily
Meng et al (2017)22 ChinaRCT13465.353.9/51.9////1 monthsACSTicagrelor 45 mg twice daily
Song et al (2017)23 ChinaRCT9562.160.6/67.730.3/293234.2/38.553.2/56.46 monthsACSTicagrelor 45 mg twice daily
Liu (2017)24 ChinaRCT7649.957.9/52.6/51.5/45.227.3/25.851.5/46.83 monthsACSTicagrelor 90 mg once daily
Li (2015)25 ChinaRCT21962.372.8/72.139.8/44.7/36.1/37.843.6/4612 monthsACSTicagrelor 45 mg twice daily
Xue et al (2016)26 ChinaRCT4060.260/70/35/6050/3025/505 daysACSTicagrelor 45 mg twice daily
  • /, not reported; ACS, acute coronary syndrome; Clo/Tic, clopidogrel/ticagrelor; DM, diabetes mellitus; HLD, hyperlipidaemia; HTN, hypertension; RCT, randomised controlled trial.